|
[1]CHOI JW, PARK JY, AHN SH, et al.Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection[J].Am J Clin Oncol, 2009, 32 (6) :564-549.
|
|
[2]LLOVET JM, REAL MI, MONTANA X, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet, 2002, 359:1734-1739.
|
|
[3]CAMMO C, SCHEPIS F, ORLANDO A, et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials[J].Radiology, 2002, 224 (1) :47-54.
|
|
[4]BEFELER AS.Chemoembolization and bland embolization:a critical appraisal[J].Clin Liver Dis, 2005, 9 (2) :287-300.
|
|
[5]TAKAYASU K, ARII S, KUDO M, et al.Superselective transarterial chemoembolization for hepatocellular carcinoma.Validation of treatment algorithm proposed by Japanese guidelines[J].J Hepatol, 2012, 56 (4) :886-892.
|
|
[6]LO CM, NGAN H, TSO WK, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology, 2002, 35 (5) :1164-1171.
|
|
[7]SANGRO B, BIBAO JI, BOAN J, et al.Radioembolization using90Y-resin microspheres for patients with advanced hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys, 2006, 66 (3) :792-800.
|
|
[8]SANGRO B, CARPANESE L, CIANNI R, et al.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages:a european evaluation[J].Hepatology, 2011, 54 (3) :868-878.
|
|
[9]CARR BI, KONDRAQUNTA V, BUCH SC, et al.Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microspheres treatments in unresectable hepatocellular carcinoma:a two-cohort study[J].Cancer, 2010, 116 (5) :1305-1314.
|
|
[10]LAMMER J, MALAGARI K, VOGL T, et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study[J].Cardiovasc Intervent Radiol, 2010, 33 (1) :41-52.
|
|
[11]LOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
|
|
[12]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebocontrolled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
|
|
[13]RICHLY H, KUPSCH P, PASSAGE K, et al.Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer[J].Int J Clin Pharmacol Ther, 2004, 42 (11) :650-651.
|
|
[14]DEL PRETE S, MONTELLA L, ADDED R, et al.Sorafenib plus long acting octreotide in advanced hepatocellular carcinoma.Preliminary results of a multicenter ongoing study[J].J Clin Oncol, 2008, 26 (19) :15624.
|
|
[15]MOORE M, HIRTE HW, SIU L, et al.Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors[J].Ann Oncol, 2005, 16 (10) :1688-1694.
|
|
[16]STRUMBERG D, VOLIOTIS D, MOELLER JG, et al.Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors[J].Int J Clin Pharmacol Ther, 2002, 40 (12) :580-581.
|
|
[17]FORNER A, LLOVET JM, BRUIX J.Sunitinib and the benefits of a negative study[J].Lancet Oncol, 2009, 10 (8) :743-744.
|
|
[18]GONG XL, QIN SK, WANG YJ, et al.Effcicacy of FOLFOX4 regimen in treatment of advanced hepatocellular carcinoma:a multicenter phaseⅡtrial[J].Chin J New Drugs, 2011, 20 (17) :1673-1677. (in Chinese) 龚新雷, 秦叔逵, 王雅杰, 等.FOLFOX4方案治疗晚期肝细胞癌的多中心Ⅱ期临床研究[J].中国新药杂志, 2011, 20 (17) :1673-1677.
|
|
[19]LIANG SX, ZHU XD, LU HJ, et al.Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma[J].Cancer, 2005, 103 (10) :2181-2188.
|
|
[20]JANG JW, KAY CS, YOU CR, et al.Simultaneous multitarget irr adiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases[J].Int J Radiat Onco l Biol Phys, 2009, 74 (2) :412-418.
|
|
[21]KWON JH, BAE SH, KIM JY, et al.Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therpy or surgical resection.Stereotactic radiothreapy for liver cancer[J].BMC Cancer, 2010, 10:475.
|
|
[22]MIZUMOTO M, TOKUUYE K, SUGAHARA S, et al.Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus:report of three cases[J].Jpn J Clin Onco l, 2007, 37 (6) :459-462.
|
|
[23]TAURA K, IKAI I, HATANO E, et al.Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection:an analysis of 610 patients over 16 years old[J].Ann Surg, 2006, 244 (2) :265-273.
|
|
[24]CHOI D, LIM HK, RHIM H, et al.Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy:long-term results and prognostic factors[J].Ann Surg Oncol, 2007, 14 (8) :2319-2329.
|
|
[25]LIANG HH, CHEN MS, PENG ZW, et al.Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma:a retrospective study[J].Ann Surg Oncol, 2008, 15 (12) :3484-3493.
|
|
[26]GOTO E, TATEISHI R, SHIINA S, et al.Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors[J].Clin Gastroenterol, 2010, 44 (5) :374-380.
|
|
[27]BECKER G, SOEZGEN T, OLSCHEWSKI M, et al.Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma[J].World J Gastroenterol, 2005, 11 (39) :6104-6109.
|
|
[28]ZHANG YJ, LIANG HH, CHEN MS, et al.Hepatocellularcarcinoma treated with radio frequency ablation with or without ethanol injection:a pro spective randomizedtrial[J].Radiology, 2007, 244 (2) :599-607.
|
DownLoad: